Maridea Wealth Management LLC Acquires New Holdings in Cellebrite DI Ltd. $CLBT

Maridea Wealth Management LLC bought a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 93,987 shares of the company’s stock, valued at approximately $1,295,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its holdings in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Cellebrite DI in the third quarter worth about $40,000. CWM LLC increased its holdings in shares of Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares in the last quarter. First Horizon Corp raised its position in shares of Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after purchasing an additional 2,337 shares during the period. Finally, Vestcor Inc bought a new position in shares of Cellebrite DI during the 3rd quarter valued at about $70,000. 45.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CLBT shares. DA Davidson assumed coverage on Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price objective for the company. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Needham & Company LLC dropped their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Insiders Place Their Bets

In other news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 13,269 shares of company stock worth $169,592. Corporate insiders own 5.70% of the company’s stock.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $13.76 on Friday. The business’s 50 day simple moving average is $13.21 and its 200 day simple moving average is $14.73. Cellebrite DI Ltd. has a 52-week low of $11.02 and a 52-week high of $19.98. The firm has a market cap of $3.43 billion, a PE ratio of 49.14, a P/E/G ratio of 1.56 and a beta of 1.17.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.